These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27027692)

  • 1. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
    [No Abstract]   [Full Text] [Related]  

  • 2. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Mora J
    Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dinutuximab approved for high-risk neuroblastoma.
    Cancer Discov; 2015 Jun; 5(6):OF5. PubMed ID: 25851859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
    Greenwood K; Foster JH
    Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Anti-NMDA Receptor Encephalitis During Dinutuximab Therapy for Neuroblastoma.
    Lowas SR; Lettieri CK
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e127-e129. PubMed ID: 31651725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma.
    Spencer K; Romberg E; Pinto N
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28147. PubMed ID: 31925911
    [No Abstract]   [Full Text] [Related]  

  • 9. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
    Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
    Greenwood KL; Foster JH
    Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Adamson PC; Park JR; Pearson AD
    Pediatr Blood Cancer; 2016 Jun; 63(6):962-3. PubMed ID: 26740172
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy.
    Marachelian A; Desai A; Balis F; Katzenstein H; Qayed M; Armstrong M; Neville KA; Cohn SL; Bush M; Gunawan R; Lim AP; Smith MA; Smith LM
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):405-12. PubMed ID: 26791869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dinutuximab: first global approval.
    Dhillon S
    Drugs; 2015 May; 75(8):923-7. PubMed ID: 25940913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restricting Access to Hope: A Parent's Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
    Bernstein J
    Pediatr Blood Cancer; 2016 Jun; 63(6):964-5. PubMed ID: 26918436
    [No Abstract]   [Full Text] [Related]  

  • 15. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Niethammer D; Berthold F
    Klin Padiatr; 2005; 217(3):147-52. PubMed ID: 15858706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.
    Gartrell J; Shulkin BL; Helmig S; Caldwell KJ; Furman W; Federico SM
    J Pediatr Hematol Oncol; 2021 Jul; 43(5):e692-e696. PubMed ID: 33181583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody therapy and neuroblastoma.
    Tao X
    N Engl J Med; 2011 Jan; 364(3):289; author reply 289-90. PubMed ID: 21247330
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
    Emberesh M; Rubinstein JD; Young J; Benoit SW; Dandoy CE; Weiss BD
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28852. PubMed ID: 33381917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.